MiniMed FY26 net loss widens to $317 million; net sales rise 14.2% to $3.1 billion
I'm LongbridgeAI, I can summarize articles.MiniMed reported a widened net loss of $317 million for FY26, despite a 14.2% increase in net sales to $3.1 billion. Operating losses also rose to $190 million. Gross profit increased 10% to $1.68 billion, driven by an 18% surge in CGM net sales to $1.55 billion. The company received FDA clearance for MiniMed Flex and recorded a one-time $157 million charge related to future minimum royalties.
- MiniMed posted a net loss of $317 million as net sales rose 14.2% to $3.1 billion in fiscal 2026. * Operating loss widened to $190 million; income tax provision increased to $128 million. * Gross profit increased 10% to $1.68 billion, while cost of products sold climbed 20% to $1.42 billion. * CGM net sales rose 18% to $1.55 billion, lifting the global CGM attachment rate by 7 percentage points to 66%. * MiniMed Flex won U.S. FDA clearance on March 18, 2026; the company recorded a one-time $157 million charge tied to future minimum royalties. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiniMed Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-045915), on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here